1. At a Glance
India Glycols Ltd (NSE: INDIAGLYCO, CMP: ₹853) is that rare desi hybrid that makes both solvents for paint companies and vodka for paint-thinners-turned-partygoers. With a market cap of ₹5,299 crore, the company posted Q1FY26 revenue of ₹1,040 crore (+7.4% YoY) and PAT of ₹73.2 crore (+21.3% YoY). ROE is 11.1%, ROCE 12.4%, debt is a chunky ₹1,892 crore (0.84x D/E), and P/E sits at 21.7x — basically cheaper than United Breweries’ froth but pricier than Tilaknagar’s desi tharra. The 6-month return is 53.8% (cheers 🥂), but the last 3 months saw a –16.6% hangover. Dividend yield at 0.59% is barely enough for one quarter peg.
2. Introduction
If Reliance is “Oil to Jio,” then India Glycols is “Grain to Gin.” Born in 1988, the company calls itself “green-tech driven.” Translation: they make chemicals from bio-based feedstocks instead of petro-based, which sounds eco-friendly until you realize they’re also India’s largest country liquor bottler in tetra packs.
Their portfolio is like a wedding buffet:
- Bulk & Specialty Chemicals for FMCG, paints, autos.
- Ethanol for OMCs because petrol apparently needs cocktail mixing too.
- IMFL brands like Soulmate Blu (whiskey), Amazing (vodka), and Zumba (rum).
- Ennature Biopharma making nutraceutical APIs like lutein and curcumin (basically turmeric capsules with a fancier label).
Geography? 91% domestic, 9% export. Basically, they’re still a ghar-ka-bazaar company. Plants? Gorakhpur, Kashipur, Dehradun — not exactly Basel or Boston, but running at 100% utilization.
In short: one company supplies ethanol to Indian Oil, vodka to Delhi bars, and thiocolchicoside to Europe. Try explaining that combo to a foreign analyst.
3. Business Model – WTF Do They Even Do?
IGL’s model is a bizarre cocktail:
- Specialty & Performance Chemicals (64%): Glycols, glycol ethers, acetates, amines, plasticizers. Basically, half of India’s FMCG and paint supply chain runs on this stuff. Think of them as the “Masala Factory” of modern industry.
- Spirits (28%): Whiskey, rum, vodka. Market leader in flavored vodka tetra packs (40%+ share). They’re like Bisleri, but for booze.
- Ennature Biopharma (7%): APIs, nutraceuticals, carotenoids, liquid nicotine. That one nerdy cousin in the family who does biotech while the rest sell booze.
- Industrial Gases: Liquid oxygen at Kashipur (60 MTPD). Because why not sell oxygen along with alcohol?
Revenue split screams dual personality disorder: one foot in the chemical lab, one foot in thekas. But maybe that’s the genius — when industrial demand slows, people still drink.
Would you trust a company that sells both ethanol to OMCs and vodka to the common man? Or is that just
